The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose-escalation study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer.
Naruo Yoshimura
No relevant relationships to disclose
Shigeki Mitsuoka
No relevant relationships to disclose
Tatsuo Kimura
No relevant relationships to disclose
Hidenori Tanaka
No relevant relationships to disclose
Tomohiro Suzumura
No relevant relationships to disclose
Misato Nagata
No relevant relationships to disclose
Kanako Umekawa
No relevant relationships to disclose
Toshiyuki Nakai
No relevant relationships to disclose
Masako Hosono Hosono
No relevant relationships to disclose
Takuhito Tada
No relevant relationships to disclose
Kazuto Hirata
No relevant relationships to disclose
Shinzoh Kudoh
No relevant relationships to disclose